Abstract
Fungal infection is an important opportunistic infection occurred in the patients with immunocompromised. Amphotericin B is an antifungal agents against Aspergillosis, however, the adverse effects is a problem for the treatment. The antifungal agents of amphotericin B drug delivery system are successful of the antifungal activity and safety. Liposomai amphotericin B (AmBisome) shows an efficacy against invasive pulmonary aspergillosis in the patients with neutropenia. Liposomal amphotericin B reduced the nephrotoxity after the therapy for the patients with invasive pulmonary aspergillosis. NS-718, a novel lipid formulation of amphotericin B, evaluated the efficacy against aspergillosis and cryptococcosis in an animal models. And NS-718 reduced the nephrotoxity in the evaluation of the cell damage to renal calls in vitro. Drug delivery system of antifungal agents is estimated the effective antifungal agents in the future.
